

Publications Involving CDRI Authors or Using CDRI Data

Dec 2019 – Dec 2022

1. Cancer in Idaho, 2020. Johnson C, Morawski B, Rycroft R, editors. Boise, ID: Cancer Data Registry of Idaho; 2022 Dec. Available at https://www.idcancer.org/ContentFiles/AnnualReports/cancer_in_idaho_2020.pdf.
2. Morawski BM, Johnson CJ, Rycroft RK. Pediatric Cancer in Idaho 2010-2019. Boise, ID: Cancer Data Registry of Idaho; 2022 June. Available at https://www.idcancer.org/ContentFiles/special/pediatric/IdahoPediatricCancer20102019_Final_508C.pdf.
3. Tanaka T, Lynch CF, Yu KJ, Morawski BM, Hsieh MC, Alverson G, Austin AA, Zeng Y, Engels EA. Pancreatic cancer among solid organ transplant recipients in the United States. *J Cancer Res Clin Oncol*. 2022. Epub 2022/08/07. doi: 10.1007/s00432-022-04227-3. PubMed PMID: 35932302.
4. Ostrom QT, Price M, Ryan K, Edelson J, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. *Neuro Oncol*. 2022;24(Suppl 3):iii1-iii38. Epub 2022/09/07. doi: 10.1093/neuonc/noac161. PubMed PMID: 36066969; PMCID: PMC9447434.
5. Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. *Neuro Oncol*. 2022;24(Supplement_5):v1-v95. Epub 2022/10/06. doi: 10.1093/neuonc/noac202. PubMed PMID: 36196752; PMCID: PMC9533228.
6. Niksic M, Matz M, Valkov M, Marcos-Gragera R, Stiller C, Rosso S, Coleman MP, Allemani C, Group CW. World-wide trends in net survival from pancreatic cancer by morphological sub-type: An analysis of 1,258,329 adults diagnosed in 58 countries during 2000-2014 (CONCORD-3). *Cancer Epidemiol*. 2022;80:102196. Epub 2022/07/17. doi: 10.1016/j.canep.2022.102196. PubMed PMID: 35841761.
7. Low JT, Ostrom QT, Cioffi G, Neff C, Waite KA, Kruchko C, Barnholtz-Sloan JS. Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. *Neurooncol Pract*. 2022;9(3):165-82. Epub 2022/05/24. doi: 10.1093/nop/npac015. PubMed PMID: 35601966; PMCID: PMC9113389.
8. Matz M, Weir HK, Alkhalawi E, Coleman MP, Allemani C, Group UCW. Disparities in cervical cancer survival in the United States by race and stage at diagnosis: An analysis of 138,883 women diagnosed between 2001 and 2014 (CONCORD-3). *Gynecol Oncol*. 2021;163(2):305-11. Epub 2021/08/30. doi: 10.1016/j.ygyno.2021.08.015. PubMed PMID: 34454725.
9. Ssenyonga N, Stiller C, Nakata K, Shalkow J, Redmond S, Bulliard JL, Girardi F, Fowler C, Marcos-Gragera R, Bonaventure A, Saint-Jacques N, Minicozzi P, De P, Rodríguez-Barranco M, Larønningen S, Di Carlo V, Mägi M, Valkov M, Seppä K, Wyn Huws D, Coleman MP, Allemani C, CONCORD Working Group. Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000-14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries. *Lancet Child Adolesc Health*. 2022 Jun;6(6):409-431. Epub 2022 Apr 22.

10. Di Carlo V, Stiller CA, Eisemann N, Bordoni A, Matz M, Curado MP, Daubisse-Marliac L, Valkov M, Bulliard JL, Morrison D, Johnson C, Girardi F, Marcos-Gragera R, Sekerija M, Laronningen S, Sirri E, Coleman MP, Allemani C, Group CW. Does the morphology of cutaneous melanoma help explain the international differences in survival? Results from 1,578,482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3). *Br J Dermatol*. 2022. Epub 2022/03/30. doi: 10.1111/bjd.21274. PubMed PMID: 35347700.
11. Hutchinson ID, Ata A, DiCaprio MR. Is Metformin Use Associated with Prolonged Overall Survival in Patients with Soft Tissue Sarcoma? A SEER-Medicare Study. *Clin Orthop Relat Res*. 2022 Apr 1;480(4):735-744.
12. Cancer in Idaho, 2019. Johnson C, Morawski B, Rycroft R, editors. Boise, ID: Cancer Data Registry of Idaho; 2021 Dec 01. Available at <https://www.idcancer.org/ContentFiles/AnnualReports/Cancer%20in%20Idaho%202019.pdf>.
13. Liu YL, Cadoo KA, Mukherjee S, Khurram A, Tkachuk K, Kemel Y, Maio A, Belhadj S, Carlo MI, Latham A, Walsh MF, Dubard-Gault ME, Wang Y, Brannon AR, Salo-Mullen E, Sheehan M, Fiala E, Devolder B, Dandiker S, Mandelker D, Zehir A, Ladanyi M, Berger MF, Solit DB, Bandlamudi C, Ravichandran V, Bajorin DF, Stadler ZK, Robson ME, Vijai J, Seshan V, Offit K. Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. *Cancer Epidemiol Biomarkers Prev*. 2022 Feb;31(2):362-371. Epub 2021 Nov 22.
14. Antwi SO, Rabe KG, Bamlet WR, Meyer M, Chandra S, Fagan SE, Hu C, Couch FJ, McWilliams RR, Oberg AL, Petersen GM. Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Probands on Concomitant Risk to First-Degree Relatives. *Cancer Epidemiol Biomarkers Prev*. 2022 Feb;31(2):372-381. Epub 2021 Nov 15.
15. Aldrighetti CM, Niemierko A, Van Allen E, Willers H, Kamran SC. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. *JAMA Netw Open*. 2021 Nov 1;4(11):e2133205.
16. Blakely AM, Nelson RA, Hamilton SA, Lai LL. Sidedness determines clinical characteristics and survival outcomes in medullary adenocarcinoma of the colon. *Sci Rep*. 2021 Oct 14;11(1):20481.
17. Forjaz G, Howlader N, Scoppa S, Johnson CJ, Mariotto AB. Impact of including second and later cancers in cause-specific survival estimates using population-based registry data. *Cancer*. 2022 Feb 1;128(3):547-557. Epub 2021 Oct 8.
18. Chiasakul T, Redd R, Patell R, Khan AM, McCarthy EP, Neuberg D, Zwicker JI. Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis. *J Thromb Haemost*. 2021 Nov;19(11):2825-2834. Epub 2021 Sep 21.
19. Chhatre S, Malkowicz SB, Jayadevappa R. Continuity of care in acute survivorship phase, and short and long-term outcomes in prostate cancer patients. *Prostate*. 2021 Dec;81(16):1310-1319. Epub 2021 Sep 13.
20. Hyer JM, Beane JD, Spolverato G, Tsilimigras DI, Diaz A, Paro A, Dalmacy D, Pawlik TM. Trends in Textbook Outcomes over Time: Are Optimal Outcomes Following Complex Gastrointestinal Surgery for Cancer Increasing? *J Gastrointest Surg*. 2022 Jan;26(1):50-59. Epub 2021 Sep 10.
21. Zhang M, Chen T, Zhong Y. Demographic and prognostic factors of optic nerve astrocytoma: a retrospective study of surveillance, epidemiology, and end results (SEER). *BMC Cancer*. 2021 Aug 30;21(1):976.
22. Hendrick RE, Monticciolo DL, Biggs KW, Malak SF. Age distributions of breast cancer diagnosis and mortality by race and ethnicity in US women. *Cancer*. 2021 Dec 1;127(23):4384-4392. Epub 2021 Aug 24.

23. Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSG, Locke FL, Brunstein CG, Merryman RW, Stiff PJ, Pawarode A, Nishihori T, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. *Transplant Cell Ther.* 2021 Nov;27(11):911.e1-911.e7. Epub 2021 Aug 24.
24. Long Parma D, Schmidt S, Muñoz E, Ramirez AG. Gastric adenocarcinoma burden and late-stage diagnosis in Latino and non-Latino populations in the United States and Texas, during 2004-2016: A multilevel analysis. *Cancer Med.* 2021 Sep;10(18):6468-6479. Epub 2021 Aug 19.
25. Mukherjee K, Davisson N, Malik S, Duszak R Jr, Kokabi N. National Utilization, Survival, and Costs Analysis of Treatment Options for Stage I Non-Small Cell Lung Cancer: A SEER-Medicare Database Analysis. *Acad Radiol.* 2022 Feb;29 Suppl 2:S173-S180. Epub 2021 Aug 14.
26. Ladbury C, Liu J, Novak J, Amini A, Glaser S. Age, racial, and ethnic disparities in reported clinical studies involving brachytherapy. *Brachytherapy.* 2022 Jan-Feb;21(1):33-42. Epub 2021 Aug 8.
27. Mukherjee K, Small W Jr, Duszak R Jr. Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016. *Brachytherapy.* 2022 Jan-Feb;21(1):12-21. Epub 2021 Aug 8.
28. Tewari P, Kashdan E, Walsh C, Martin CM, Parnell AC, O'Leary JJ. Estimating the conditional probability of developing human papilloma virus related oropharyngeal cancer by combining machine learning and inverse Bayesian modelling. *PLoS Comput Biol.* 2021 Aug 20;17(8):e1009289. doi: 10.1371/journal.pcbi.1009289. eCollection 2021 Aug.
29. Segel JE, Schaefer EW, Zaorsky NG, Hollenbeak CS, Ramian H, Raman JD. Potential Winners and Losers: Understanding How the Oncology Care Model May Differentially Affect Hospitals. *JCO Oncol Pract.* 2021 Aug;17(8):e1150-e1161. Epub 2021 Jul 9.
30. Yan CH, Coleman C, Nabulsi NA, Chiu BC, Ko NY, Hoskins K, Calip GS. Associations between frailty and cancer-specific mortality among older women with breast cancer. *Breast Cancer Res Treat.* 2021 Oct;189(3):769-779. Epub 2021 Jul 9.
31. Howard DH, Quek RGW, Fox KM, Arondekar B, Filson CP. The value of new drugs for advanced prostate cancer. *Cancer.* 2021 Sep 15;127(18):3457-3465. Epub 2021 Jun 1.
32. Kensler KH, Pernar CH, Mahal BA, Nguyen PL, Trinh QD, Kibel AS, Rebbeck TR. Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. *J Natl Cancer Inst.* 2021 Jun 1;113(6):719-726.
33. Ton M, Widener MJ, James P, VoPham T. Food Environments and Hepatocellular Carcinoma Incidence. *Int J Environ Res Public Health.* 2021 May 27;18. (11).
34. Lamba N, Catalano PJ, Whitehouse C, Martin KL, Mendu ML, Haas-Kogan DA, Wen PY, Aizer AA. Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis. *Neurooncol Pract.* 2021 May 21;8(5):569-580. doi: 10.1093/nop/npab029. eCollection 2021 Oct.
35. Grady I, Grady S, Chanisheva N. Long-term cost of breast cancer treatment to the United States Medicare Program by stage at diagnosis. *Eur J Health Econ.* 2021 Dec;22(9):1365-1370. Epub 2021 May 18.
36. Showalter SL, Meneveau MO, Keim-Malpass J, Camacho TF, Squeo G, Anderson RT. Effects of Adjuvant Endocrine Therapy Adherence and Radiation on Recurrence and Survival Among Older Women with Early-Stage Breast Cancer. *Ann Surg Oncol.* 2021 Nov;28(12):7395-7403. Epub 2021 May 12.
37. Talon B, Calip GS, Lee TA, Sharp LK, Patel P, Touchette DR. Trend in Tyrosine Kinase Inhibitor Utilization, Price, and Out-of-Pocket Costs in Patients With Chronic

- Myelogenous Leukemia. *JCO Oncol Pract*. 2021 Nov;17(11):e1811-e1820. Epub 2021 May 7.
38. Gondi S, Wright AA, Landrum MB, Meneades L, Zubizarreta J, Chernen ME, Keating NL. Assessment of Patient Attribution to Care From Medical Oncologists, Surgeons, or Radiation Oncologists After Newly Diagnosed Cancer. *JAMA Netw Open*. 2021 May 3;4(5):e218055.
 39. Johnson CJ, Morawski BM, Rycroft RK. Pediatric Cancer in Idaho 2009-2018. Boise, ID: Cancer Data Registry of Idaho; 2021 May 01. Available at https://www.idcancer.org/ContentFiles/special/pediatric/IdahoPediatricCancer2009_2018.pdf.
 40. Cancer County Profiles 2014-2018 Incidence Years. Johnson C, Morawski B, editors. Boise, ID: Cancer Data Registry of Idaho; 2021 May 01. Available at [https://www.idcancer.org/ContentFiles/special/CountyProfiles/All%20Idaho%20Counties/Idaho CCP 1418.pdf](https://www.idcancer.org/ContentFiles/special/CountyProfiles/All%20Idaho%20Counties/Idaho_CCP_1418.pdf).
 41. Mullins MA, Ruterbusch JJ, Clarke P, Uppal S, Cote ML, Wallner LP. Continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer. *Gynecol Oncol*. 2021 Jul;162(1):148-153. Epub 2021 Apr 28.
 42. Azap RA, Diaz A, Hyer JM, Tsilimigras DI, Mirdad RS, Ejaz A, Pawlik TM. Impact of Race/Ethnicity and County-Level Vulnerability on Receipt of Surgery Among Older Medicare Beneficiaries With the Diagnosis of Early Pancreatic Cancer. *Ann Surg Oncol*. 2021 Oct;28(11):6309-6316. Epub 2021 Apr 12.
 43. Ni K, Yang JY, Baeg K, Leiter AC, Mhango G, Gallagher EJ, Wisnivesky JP, Kim MK. Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients. *Cancer Rep (Hoboken)*. 2021 Oct;4(5):e1387. Epub 2021 Apr 9.
 44. Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, Jabbour E, Kantarjian HM. De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. *Cancer*. 2021 Jun 15;127(12):2049-2061. Epub 2021 Apr 5.
 45. Gallicchio L, Dae DL, Rotunno M, Barajas R, Fagan S, Carrick DM, Divi RL, Filipinski KK, Freedman AN, Gillanders EM, Lam TK, Martin DN, Rogers S, Verma M, Nelson SA. Epidemiologic Research of Rare Cancers: Trends, Resources, and Challenges. *Cancer Epidemiol Biomarkers Prev*. 2021 Jul;30(7):1305-1311. Epub 2021 Apr 1.
 46. Sieluk J, Yang L, Haiderali A, Huang M, Hirshfield KM. Systemic therapy, survival and end-of-life costs for metastatic triple-negative breast cancer: retrospective SEER-Medicare study of women age ≥ 65 years. *Future Oncol*. 2021 Jul;17(20):2581-2592. Epub 2021 Mar 25.
 47. Johnson CJ, Morawski BM, Hobbs L, Lewis D, Cariou C, Rycroft RK. Time from breast cancer diagnosis to treatment among Idaho's National Breast and Cervical Cancer Early Detection Program population, 2011-2017. *Cancer Causes Control*. 2021 Jun;32(6):667-673. Epub 2021 Mar 4.
 48. Luan D, Wu Y, Goldstein J, Rutherford S, Leonard JP, Martin P. Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset. *Leuk Lymphoma*. 2021 Aug;62(8):1850-1859. Epub 2021 Feb 25.
 49. Mullins MA, Ruterbusch JJ, Clarke P, Uppal S, Wallner LP, Cote ML. Trends and racial disparities in aggressive end-of-life care for a national sample of women with ovarian cancer. *Cancer*. 2021 Jul 1;127(13):2229-2237. Epub 2021 Feb 25.

50. Mirdad RS, Madison Hyer J, Diaz A, Tsilimigras DI, Azap RA, Paro A, Pawlik TM. Postoperative imaging surveillance for hepatocellular carcinoma: How much is enough? *J Surg Oncol*. 2021 Jun;123(7):1568-1577. Epub 2021 Feb 17.
51. Rice DR, Hyer JM, Diaz A, Pawlik TM. End-of-Life Hospice Use and Medicare Expenditures Among Patients Dying of Hepatocellular Carcinoma. *Ann Surg Oncol*. 2021 Sep;28(9):5414-5422. Epub 2021 Feb 2.
52. Azap RA, Hyer JM, Diaz A, Paredes AZ, Pawlik TM. Association of County-Level Vulnerability, Patient-Level Race/Ethnicity, and Receipt of Surgery for Early-Stage Hepatocellular Carcinoma. *JAMA Surg*. 2021 Feb 1;156(2):197-199.
53. Wong RJ, Saab S, Konyon P, Sundaram V, Khalili M. Rural-Urban Geographical Disparities in Hepatocellular Carcinoma Incidence Among US Adults, 2004-2017. *Am J Gastroenterol*. 2021 Feb 1;116(2):401-406.
54. Mian HS, Fiala MA, Sanchez L, Vij R, Wildes TM. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world". *Ann Hematol*. 2021 May;100(5):1261-1266. Epub 2021 Jan 21.
55. Yang SC, Gross C, Wang JD, Wang SY. Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008-2016. *J Gen Intern Med*. 2021 Nov;36(11):3589-3591. Epub 2021 Jan 19.
56. Tsilimigras DI, Hyer JM, Diaz A, Moris D, Abbas A, Dillhoff M, Cloyd JM, Ejaz A, Beane JD, Tsung A, Pawlik TM. Impact of cancer center accreditation on outcomes of patients undergoing resection for hepatocellular carcinoma: A SEER-Medicare analysis. *Am J Surg*. 2021 Sep;222(3):570-576. Epub 2021 Jan 13.
57. Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, Guerin A, Wu EQ, Sadek I, Cao X. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. *Leuk Lymphoma*. 2021 Jun;62(6):1411-1421. Epub 2021 Jan 11.
58. Lamba N, Catalano PJ, Cagney DN, Haas-Kogan DA, Bublick EJ, Wen PY, Aizer AA. Seizures Among Patients with Brain Metastases: A Population- and Institutional-level Analysis. *Neurology*. 2021 Jan 5. Epub 2021 Jan 5.
59. Herb J, Wolff R, McDaniel P, Holmes M, Lund J, Stitzenberg K. Rural representation of the surveillance, epidemiology, and end results database. *Cancer Causes Control*. 2021 Mar;32(3):211-220. Epub 2021 Jan 3.
60. Kuai L, Zhang Y, Luo Y, Li W, Li XD, Zhang HP, Liu TY, Yin SY, Li B. Prognostic Nomogram for Liver Metastatic Colon Cancer Based on Histological Type, Tumor Differentiation, and Tumor Deposit: A TRIPOD Compliant Large-Scale Survival Study. *Front Oncol*. 2021 Oct 12;11:604882. doi: 10.3389/fonc.2021.604882. eCollection 2021.
61. Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, Guérin A, Wu EQ, Sadek I, Cao X. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. *J Med Econ*. 2021 Jan-Dec;24(1):234-243.
62. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. *Neuro Oncol*. 2021;23(12 Suppl 2):iii1-iii105. Epub 2021/10/06. doi: 10.1093/neuonc/noab200. PubMed PMID: 34608945; PMCID: PMC8491279.
63. Teng H, Liu Z, Yan O, He W, Jie D, Qie Y, Xu J. Nomograms for Predicting Overall Survival Among Patients with Craniopharyngiomas at Initial Diagnosis: A SEER Population-Based Analysis. *Int J Gen Med*. 2021 Jul 15;14:3517-3527. doi: 10.2147/IJGM.S320643. eCollection 2021.

64. Forjaz G, Barnholtz-Sloan JS, Kruchko C, Siegel R, Negoita S, Ostrom QT, Dickie L, Ruhl J, Van Dyke A, Patil N, Cioffi G, Miller KD, Waite K, Mariotto AB. An updated histology recode for the analysis of primary malignant and nonmalignant brain and other central nervous system tumors in the Surveillance, Epidemiology, and End Results Program. *Neurooncol Adv.* 2020 Dec 8;3(1):vdad175. doi: 10.1093/neoajnl/vdad175. eCollection 2021 Jan-Dec.
65. Cancer in Idaho, 2018. Johnson C, Morawski B, Rycroft R, editors. Boise, ID: Cancer Data Registry of Idaho; 2020 Dec 01. Available at <https://www.idcancer.org/ContentFiles/AnnualReports/Cancer%20in%20Idaho%202018.pdf>.
66. Zahnd WE, Gomez SL, Steck SE, Brown MJ, Ganai S, Zhang J, Arp Adams S, Berger FG, Eberth JM. Rural-urban and racial/ethnic trends and disparities in early-onset and average-onset colorectal cancer. *Cancer.* 2021 Jan 15;127(2):239-248. Epub 2020 Oct 28.
67. Fraser GE, Jaceldo-Siegl K, Orlich M, Mashchak A, Sirirat R, Knutsen S. Dairy, soy, and risk of breast cancer: those confounded milks. *Int J Epidemiol.* 2020 Oct 1;49(5):1526-1537.
68. Papenberg BW, Allen JL, Markwell SM, Interval ET, Montague PA, Johnson CJ, Weed SA. Disparate survival of late-stage male oropharyngeal cancer in Appalachia. *Sci Rep.* 2020 Jul 15;10(1):11612.
69. Johnson CJ, Willming M, Paden N. Detection of clusters of lung cancer incidence in Idaho with ecological adjustment for smoking, radon, fine particulate air pollution, elevation, and socioeconomic position. Boise, ID: Cancer Data Registry of Idaho; 2020 Jul 01. Available at <https://www.idcancer.org/ContentFiles/special/Idaho%20lung%20cancer%20incidence%20patterns%202007-2016.pdf>.
70. Morawski BM, Qiao B, Coyle L, Rycroft RK, Schymura MJ, Johnson CJ. Impact of Linkage to the Social Security Administration on Follow-up Completeness and Cancer Relative Survival Estimates in 2 New SEER Registries: 2000-2016 Diagnosis Years. *J Registry Manag.* 2020 Summer;47(2):37-47.
71. Schwartz CT, Ezaldein HH, Merati M. Ultraviolet Light Gel Manicures: Is There a Risk of Skin Cancer on the Hands and Nails of Young Adults? *J Clin Aesthet Dermatol.* 2020 Jul;13(7):45-46. Epub 2020 Jul 1.
72. Colbeth HL, Genere N, Hall CB, Jaber N, Brito JP, El Kawkgi OM, Goldfarb DG, Webber MP, Schwartz TM, Prezant DJ, Zeig-Owens R. Evaluation of Medical Surveillance and Incidence of Post-September 11, 2001, Thyroid Cancer in World Trade Center-Exposed Firefighters and Emergency Medical Service Workers. *JAMA Intern Med.* 2020 Jun 1;180(6):888-895.
73. Johnson CJ, Morawski BM, Rycroft RK. Pediatric Cancer in Idaho 2008-2017. Boise, ID: Cancer Data Registry of Idaho; 2020 May 01. Available at https://www.idcancer.org/ContentFiles/special/pediatric/IdahoPediatricCancer2008_2017.pdf.
74. Zheng E, Yang M, Li R, Ni J, Xu X, Zhao G. Prognostic impact of lymphadenectomy on outcomes of sublobar resection for non-small cell lung cancer ≤ 1 or >1 to 2 cm. *J Thorac Dis.* 2020 May;12(5):2049-2060.
75. Pierre-Victor D, Pinsky PF, McCaskill-Stevens W. Other- and all-cause Mortality among women with breast cancer. *Cancer Epidemiol.* 2020 Apr;65:101694. Epub 2020 Mar 2.
76. Zhou Y, Zhang R, Ding Y, Wang Z, Yang C, Tao S, Liang C. Prognostic nomograms and Aggtrmmns scoring system for predicting overall survival and cancer-specific survival of patients with kidney cancer. *Cancer Med.* 2020 Apr;9(8):2710-2722. Epub 2020 Feb 22.

77. Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, Lewis SJ, Relton CL, Martin RM. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer. *JAMA*. 2020 Feb 18;323(7):646-655.
78. Zhang H, Naji Y, Yan M, Lian W, Xie M, Dai Y. Development and validation of prognostic nomograms in patients with adrenocortical carcinoma: a population-based study. *Int Urol Nephrol*. 2020 Jun;52(6):1057-1071. Epub 2020 Feb 18.
79. Shiels MS, O'Brien TR. Recent Decline in Hepatocellular Carcinoma Rates in the United States. *Gastroenterology*. 2020 Apr;158(5):1503-1505.e2. Epub 2020 Jan 19.
80. Thompson TD, Pollack LA, Johnson CJ, Wu XC, Rees JR, Hsieh MC, Rycroft R, Culp M, Wilson R, Wu M, Zhang K, Benard V. Breast and colorectal cancer recurrence and progression captured by five U.S. population-based registries: Findings from National Program of Cancer Registries patient-centered outcome research. *Cancer Epidemiol*. 2020 Feb;64:101653. Epub 2020 Jan 6.
81. Lu Y, Zhang W, Fan S, Liang Z, Li Z, Tian J, Kang J, Song Y, Liu K, Zhou K, Wang X, Yang Y, Liu X. Metabolic Syndrome and Risk of Upper Tract Urothelial Carcinoma: A Case-Control Study From Surveillance, Epidemiology and End Results-Medicare-Linked Database. *Front Oncol*. 2021 Jan 21;10:613366. doi: 10.3389/fonc.2020.613366. eCollection 2020.
82. Quick AM, Krok-Schoen JL, Stephens JA, Fisher JL. Cervical Cancer Among Older Women: Analyses of Surveillance, Epidemiology and End Results Program Data. *Cancer Control*. 2020 Jan-Dec;27(1):1073274820979590.
83. Cancer County Profiles 2013-2017 Incidence Years. Johnson C, Morawski B, editors. Boise, ID: Cancer Data Registry of Idaho; 2020 Jan 01. Available at https://www.idcancer.org/ContentFiles/special/CountyProfiles/All%20Idaho%20Counties/Idaho_CCP_1317.pdf.
84. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020 Jan;70(1):7-30. Epub 2020 Jan 8.
85. Wong RJ, Kim D, Ahmed A, Singal AK. Patients with hepatocellular carcinoma from more rural and lower-income households have more advanced tumor stage at diagnosis and significantly higher mortality. *Cancer*. 2020 Jan 1;127(1):45-55. Epub 2020 Oct 26.
86. Zhao S, Zhu H, Jiao R, Wu X, Zhang X, Ji G. Primary Tumor Resection Improves Survival in Patients With Metastatic Gastrointestinal Stromal Tumors: A Preliminary Population-Based Analysis. *Front Oncol*. 2020 Aug 19;10:1440. doi: 10.3389/fonc.2020.01440. eCollection 2020.
87. Cancer in Idaho, 2017. Johnson C, Morawski B, Rycroft R, editors. Boise, ID: Cancer Data Registry of Idaho; 2019 Dec 01. Available at <https://www.idcancer.org/ContentFiles/AnnualReports/Cancer%20in%20Idaho%202017.pdf>.
88. Yin M, Zhao J, Monk P, Martin D, Folefac E, Joshi M, Jin N, Mortazavi A, Verschraegen C, Clinton S. Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer. *Cancer Med*. 2020 Jan;9(1):27-34. Epub 2019 Nov 7.